Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

exact sciences corp. - EXAS

EXAS

Close Chg Chg %
101.36 0.13 0.12%

Open Market

101.49

+0.13 (0.12%)

Volume: 656.52K

Last Updated:

Dec 12, 2025, 11:17 AM EDT

Trade Now

Company Overview: exact sciences corp. - EXAS

EXAS Key Data

Open

$101.40

 Day Range

101.38 - 101.59

52 Week Range

38.88 - 101.95

 Market Cap

$19.21B

Shares Outstanding

189.77M

 Public Float

186.70M

Beta

1.42

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$5.32

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

10.45M

  

EXAS Performance

1 Week
 
 0.30%
 
1 Month
 
 51.22%
 
3 Months
 
 87.91%
 
1 Year
 
 65.49%
 
5 Years
 
 -21.73%
 

EXAS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 24
Full Ratings ➔

About exact sciences corp. - EXAS

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

EXAS At a Glance

EXACT Sciences Corp.
5505 Endeavor Lane
Madison, Wisconsin 53719
Phone 1-608-284-5700 Revenue 2.76B
Industry Medical Specialties Net Income -1,028,857,000.00
Sector Health Technology 2024 Sales Growth 10.365%
Fiscal Year-end 12 / 2025 Employees 7,000
View SEC Filings

EXAS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.752
Price to Book Ratio 4.342
Price to Cash Flow Ratio 49.16
Enterprise Value to EBITDA 523.937
Enterprise Value to Sales 4.381
Total Debt to Enterprise Value 0.23

EXAS Efficiency

Revenue/Employee 394,123.857
Income Per Employee -146,979.571
Receivables Turnover 10.897
Total Asset Turnover 0.421

EXAS Liquidity

Current Ratio 2.146
Quick Ratio 1.924
Cash Ratio 1.418

EXAS Profitability

Gross Margin 69.547
Operating Margin -6.952
Pretax Margin -37.557
Net Margin -37.293
Return on Assets -15.716
Return on Equity -37.092
Return on Total Capital -19.87
Return on Invested Capital -19.557

EXAS Capital Structure

Total Debt to Total Equity 115.548
Total Debt to Total Capital 53.607
Total Debt to Total Assets 44.974
Long-Term Debt to Equity 103.711
Long-Term Debt to Total Capital 48.115
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Exact Sciences Corp. - EXAS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.77B 2.08B 2.50B 2.76B
Sales Growth
+18.49% +17.95% +19.93% +10.37%
Cost of Goods Sold (COGS) incl D&A
553.76M 671.84M 746.41M 840.15M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
206.17M 226.20M 234.50M 214.86M
Depreciation
111.17M 128.75M 142.34M 119.70M
Amortization of Intangibles
95.00M 97.45M 92.16M 95.16M
COGS Growth
+23.68% +21.32% +11.10% +12.56%
Gross Income
1.21B 1.41B 1.75B 1.92B
Gross Income Growth
+16.26% +16.41% +24.14% +9.43%
Gross Profit Margin
+68.66% +67.77% +70.14% +69.55%
2021 2022 2023 2024 5-year trend
SG&A Expense
1.94B 2.03B 2.06B 2.11B
Research & Development
300.35M 393.42M 425.88M 431.21M
Other SG&A
1.64B 1.64B 1.64B 1.68B
SGA Growth
+63.50% +4.67% +1.52% +2.24%
Other Operating Expense
- - - -
-
Unusual Expense
95.97M (40.65M) (7.10M) 846.61M
EBIT after Unusual Expense
(825.18M) (580.27M) (303.76M) (1.04B)
Non Operating Income/Expense
1.28M (32.67M) 111.14M 34.81M
Non-Operating Interest Income
- - - 1.79M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
18.61M 19.63M 9.12M 32.57M
Interest Expense Growth
-78.86% +5.53% -53.53% +256.99%
Gross Interest Expense
18.61M 19.63M 9.12M 32.57M
Interest Capitalized
- - - -
-
Pretax Income
(842.51M) (632.57M) (201.75M) (1.04B)
Pretax Income Growth
+1.70% +24.92% +68.11% -413.60%
Pretax Margin
-47.68% -30.35% -8.07% -37.56%
Income Tax
(246.88M) (9.06M) 2.40M (7.30M)
Income Tax - Current - Domestic
1.39M 2.17M 2.27M 933.00K
Income Tax - Current - Foreign
4.90M 1.13M 2.56M 1.88M
Income Tax - Deferred - Domestic
(253.22M) (12.22M) 566.00K (9.92M)
Income Tax - Deferred - Foreign
54.00K (147.00K) (2.99M) (199.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(595.63M) (623.51M) (204.15M) (1.03B)
Minority Interest Expense
- - - -
-
Net Income
(595.63M) (623.51M) (204.15M) (1.03B)
Net Income Growth
+29.81% -4.68% +67.26% -403.97%
Net Margin Growth
-33.71% -29.91% -8.17% -37.29%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(595.63M) (623.51M) (204.15M) (1.03B)
Preferred Dividends
- - - -
-
Net Income Available to Common
(595.63M) (623.51M) (204.15M) (1.03B)
EPS (Basic)
-3.4761 -3.5356 -1.1332 -5.5856
EPS (Basic) Growth
+38.08% -1.71% +67.95% -392.91%
Basic Shares Outstanding
171.35M 176.35M 180.14M 184.20M
EPS (Diluted)
-3.4761 -3.5356 -1.1332 -5.5856
EPS (Diluted) Growth
+38.08% -1.71% +67.95% -392.91%
Diluted Shares Outstanding
171.35M 176.35M 180.14M 184.20M
EBITDA
(523.04M) (394.72M) (76.36M) 23.07M
EBITDA Growth
-1,608.88% +24.53% +80.65% +130.21%
EBITDA Margin
-29.60% -18.94% -3.05% +0.84%

Snapshot

Average Recommendation HOLD Average Target Price 100.313
Number of Ratings 24 Current Quarters Estimate -0.081
FY Report Date 12 / 2025 Current Year's Estimate -0.703
Last Quarter’s Earnings -0.10 Median PE on CY Estimate N/A
Year Ago Earnings -5.59 Next Fiscal Year Estimate 0.372
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 9 12 13
Mean Estimate -0.08 -0.19 -0.70 0.37
High Estimates 0.06 0.05 -0.56 1.08
Low Estimate -0.36 -0.58 -1.00 -0.24
Coefficient of Variance -140.08 -90.21 -16.24 96.79

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 19
OVERWEIGHT 1 1 4
HOLD 20 20 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Buy

Insider Actions for Exact Sciences Corp. - EXAS

Date Name Shares Transaction Value
Apr 18, 2025 Aaron Bloomer EVP, Chief Financial Officer 11,556 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Aaron Bloomer EVP, Chief Financial Officer 6,436 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $44.25 per share 284,793.00
Apr 18, 2025 Aaron Bloomer EVP, Chief Financial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Aaron Bloomer EVP, Chief Financial Officer 38,715 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 18, 2025 Aaron Bloomer EVP, Chief Financial Officer 13,623 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $44.25 per share 602,817.75
Apr 18, 2025 Aaron Bloomer EVP, Chief Financial Officer 19,340 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 Kevin T. Conroy President and CEO; Director 1,203,269 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $22.38 per share 26,929,160.22
Mar 11, 2025 Kevin T. Conroy President and CEO; Director 1,154,340 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $47.06 per share 54,323,240.40
Mar 11, 2025 Kevin T. Conroy President and CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 27, 2025 Jake Orville EVP, GM, Screening 22,136 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 27, 2025 Sarah Condella EVP, Human Resources 3,955 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 27, 2025 Sarah Condella EVP, Human Resources 23,817 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Sarah Condella EVP, Human Resources 78,438 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.28 per share 4,022,300.64
Feb 27, 2025 Jake Orville EVP, GM, Screening 3,955 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 27, 2025 Jake Orville EVP, GM, Screening 28,779 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 James M. Herriott SVP, General Counsel & Sec 13,893 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2025 Jake Orville EVP, GM, Screening 20,277 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.28 per share 1,039,804.56
Feb 27, 2025 Brian Baranick EVP, GM, Precision Oncology 19,841 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 27, 2025 Brian Baranick EVP, GM, Precision Oncology 17,833 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $51.28 per share 914,476.24
Feb 27, 2025 Brian Baranick EVP, GM, Precision Oncology 28,779 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Exact Sciences Corp. in the News